Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladarixin in Recent Onset Type 1 Diabetes With Low Residual β-cell Function
2024-513560-26-00Phase 2Completed
- Sponsor
- Dompé
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Ladarixin with Placebo (2 arms). Primary endpoint: Change from baseline in 2-hour AUC of C-peptide response to the MMTT at Month 6. Started Sep 2024; status: completed.
02
Drugs
ladarixin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-513560-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513560-26-00.